# Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

> **NCT01575548** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 129 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Stage IV Renal Cell Cancer AJCC v7

## Interventions

- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Pazopanib Hydrochloride
- **OTHER:** Placebo Administration
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT01575548
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-08-08
- **Primary completion:** 2018-07-17
- **Final completion:** 2027-02-20
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01575548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01575548, "Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01575548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*